6
Minutes read

Trade During a Pandemic

Authors
Aidonna Jan Ayub
No items found.
Key Takeaways
Data Overview
- In 2018, Malaysia imported approximately USD2.4bn (RM9.5bn) of Covid-19 medical supplies. This paper highlights three areas where greater alignment can be made between trade and public health policy, as listed below.
- Reassess the need for tariffs and excise duties on medical supplies. Malaysia has the good practice of not imposing tariffs on most of the Covid-19 medical supplies. Nevertheless, there are five specific product categories where Malaysia does apply most favoured nation (MFN) tariff rates. However, in three of these products, preferential tariff rates are at 0% as for example in ASEAN. Malaysia also imposes excise duties on two product categories. Given that ASEAN and other importers already enjoy 0% tariffs, the cost of temporarily waiving tariffs on medical products may not be overly burdensome on government revenues. There is also a need to review Malaysia’s immediate needs on raw materials for the domestic production of medical supplies. Worldwide, some countries have taken proactive steps to unilaterally, temporarily suspend specific tariff and non-tariff measures.
- Review Malaysia’s non-tariff measures (NTMs) on medical supplies. NTMs may have important restrictive and/or distortionary effects on trade. Prior to the Covid-19 pandemic, Malaysia had NTMs for the importation of 23 product categories on the medical supplies list. This calculation of NTMs exclude measures imposed for health and safety purposes. Therefore, a careful review of these NTMs could reveal measures that can be suspended during this pandemic – thus improving the import and export of medical supplies.
- Monitor and engage with Malaysia’s trading partners. In March 2020, at least 33 out of 46 export curbs were announced by 54 governments in total.[1] This is an indication of the speed in which countries are imposing export restrictions. Malaysia is currently most affected by India’s export restrictions on medical supplies, followed by Indonesia, Switzerland and the European Union (EU). Therefore, Malaysian businesses and the governent will need to be vigilant of these developments and quickly adjust to potential shortfalls in import items. This is particularly important for medical supplies that are not produced domestically.
trade-during-a-pandemic
Discussion Papers
Peer-reviewed publications designed to share emerging research or early analysis on key issues. Discussion Papers aim to invite feedback, encourage dialogue, and inspire further study or collaboration.
Disclaimer
As we transition to a digital-first communication and continue building our knowledge hub, publications released before October 2025 are preserved in their original format. Publications released from October 2025 onward adopt a new, digitally friendly format for easier online reading. The official versions of earlier publications, including their original language and formatting, remain available in the downloadable PDF.
- In 2018, Malaysia imported approximately USD2.4bn (RM9.5bn) of Covid-19 medical supplies. This paper highlights three areas where greater alignment can be made between trade and public health policy, as listed below. - Reassess the need for tariffs and excise duties on medical supplies. Malaysia has the good practice of not imposing tariffs on most of the Covid-19 medical supplies. Nevertheless, there are five specific product categories where Malaysia does apply most favoured nation (MFN) tariff rates. However, in three of these products, preferential tariff rates are at 0% as for example in ASEAN. Malaysia also imposes excise duties on two product categories. Given that ASEAN and other importers already enjoy 0% tariffs, the cost of temporarily waiving tariffs on medical products may not be overly burdensome on government revenues. There is also a need to review Malaysia’s immediate needs on raw materials for the domestic production of medical supplies. Worldwide, some countries have taken proactive steps to unilaterally, temporarily suspend specific tariff and non-tariff measures. - Review Malaysia’s non-tariff measures (NTMs) on medical supplies. NTMs may have important restrictive and/or distortionary effects on trade. Prior to the Covid-19 pandemic, Malaysia had NTMs for the importation of 23 product categories on the medical supplies list. This calculation of NTMs exclude measures imposed for health and safety purposes. Therefore, a careful review of these NTMs could reveal measures that can be suspended during this pandemic – thus improving the import and export of medical supplies. - Monitor and engage with Malaysia’s trading partners. In March 2020, at least 33 out of 46 export curbs were announced by 54 governments in total.[1] This is an indication of the speed in which countries are imposing export restrictions. Malaysia is currently most affected by India’s export restrictions on medical supplies, followed by Indonesia, Switzerland and the European Union (EU). Therefore, Malaysian businesses and the governent will need to be vigilant of these developments and quickly adjust to potential shortfalls in import items. This is particularly important for medical supplies that are not produced domestically.
Read Full Publication

Article highlight

featured report

Conclusion

Attributes
Footnotes
References
Photography Credit

Related to this Publication

No results found for this selection
You can  try another search to see more

Want more stories like these in your inbox?

Stay ahead with KRI, sign up for research updates, events, and more

Thanks for subscribing. Your first KRI newsletter will arrive soon—filled with fresh insights and research you can trust.

Oops! Something went wrong while submitting the form.
Follow Us On Our Socials